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A small group of HIV-1 -infected subjects who  either  do not progress to AIDS or progress only  slowly  have  sustained HIV-1- 
specific CTL responses. It has been suggested that the specificities of these responses differ from the CTL responses of rapid 
progressors  due to  recognition of epitopes  that  are  under  structural  or functional constraints. We have, in this respect,  studied 
the CTL response to reverse  transcriptase  (RT) in long term survivors (LTS) and in  HIV-I-infected individuals  who progressed 
to AIDS within 3 to 6 yr. Both LTS and progressors displayed vigorous RT-specific CTL responses of comparable magnitude 
during the asymptomatic phase. From each individual at least two CTL lines were obtained from blood samples drawn at 
different time points  during follow-up. A total of 19 CTL  lines recognized  nine  different  RT-derived  epitopes. CTL obtained from 
progressors recognized epitopes with a similar degree of amino acid conservation as epitopes targeted by CTL from LTS. 
Furthermore, five of seven  epitopes were recognized by both LTS and  progressors. Moreover, one of the  epitopes  recognized 
by progressors contained the highly conserved YMDD motif that is essential for RT activity. In conclusion,  our  data imply that 
neither the magnitude  nor  the  specificity  of HIV-I-specific CTL against RT i s  a  major cause of a more protracted course of 
disease. The Journal of Immunology, 1997, 159: 3648-3654. 
V irus-specific CTL are believed to control and are some- times able to clear most viral infections. The decrease in HIV-I viral load following the appearance of HIV-I- 
specific CTL during primary HIV-I infection (l), a temporal as- 
sociation between persistent CTL activity and stable viral load in 
the asymptomatic phase (2), together with the demonstration that 
CTL efficiently suppress HIV-I replication in vitro (3) are thought 
to reflect the efficacy  of HIV-I-specific CTL. 
A minority of HIV-1-infected subjects do not progress to AIDS, 
although they have been infected with HIV-1 for >lo yr. These 
so-called long term survivors (LTS)4 maintain persistent and 
broadly directed CTL responses with low numbers of HIV-I-in- 
fected cells. In contrast, most infected persons lose HIV- 1 -specific 
CTL activity during progression to AIDS, and this is paralleled by 
an increase in viral load (2, 4-9). This suggests that HIV-I-spe- 
cific CTL may be involved in delaying progression to AIDS. The 
HIV- 1 -specific T cell response of LTS may be distinct from that of 
progressors in several aspects. First, LTS might display higher 
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levels of peripheral expansion of HIV- 1-specific CTL, resulting in 
the generation of more effector cells. Another possibility is that 
CTL from LTS target more viral proteins (i.e., epitopes) at the 
same time. As for the latter, i t  has been shown that subjects who 
progressed to AIDS displayed strong HIV-I-specific CTL re- 
sponses against all major proteins during their asymptomatic 
phase' (2, 10). It seems therefore unlikely that the magnitude or 
the breadth of the CTL response discriminates long term survival 
from progression to AIDS. Another possibility could be the bio- 
physical properties of the CTL-targeted epitopes that impact on the 
outcome of disease. LTS might recognize epitopes that are ex- 
pressed early in the life cycle of the virus and kill infected cells 
before new virions are released. Alternatively, epitopes that do not 
display sequence variation because of functional or structural con- 
strdints might be recognized, which makes i t  difficult for the virus 
to escape from CTL (7, 11-17). 
Hitherto many CTL epitopes have been described but their clin- 
ical importance has not been established, since clinical follow-up 
data for most patients have not been reported. In addition, se- 
quences of some proteins (e.g., Env) in laboratory HIV-I strains 
might have little homology with those that affected these HIV- I - 
infected individuals. We wanted to study whether qualitative dif- 
ferences exist in  epitopes recognized by CTL from LTS and pro- 
gressors. For this purpose we studied the CTL response to reverse 
transcriptase (RT), since this protein exhibits minor variation 
among sequenced isolates and is functionally essential for viral 
replication. Moreover, RT is a major target for virus-specific CTL 
at various stages of HIV-1 infection (18). For these reasons, se- 
quence variation in RT-derived CTL epitopes would interfere with 
HIV-1 replication. We made an inventory of viral epitopes recog- 
nized by immunodominant CTL directed against RT  in a  group of 
HIV- I -infected individuals consisting of four LTS (asymptomatic 
' 0. Pontesilli, M. R. Klein. S. Kerkhof-Garde, N. Pakker, f. de Wolf, H. Schutte- 
maker, and F. Miedema. 1997. Kinetics of HIV-1 specific cylotoxic T lymphocyte 
responses and viral load in the natural history of HIV-1 infection. Submitted for 
publicatton. 
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>10 yr, with normal CD4" T cell counts) and three (rapid) pro- 
gressors from the Amsterdam Cohort Studies on HIV-1 infection 
and  AIDS. No differences were found between these individuals in 
either the magnitude of the total RT-specific CTL response or in 
the level of conservation of the epitopes. 
Materials and Methods 
Study population 
The Amsterdam Cohort Studies on HIV Infection and AIDS were initiated 
in October 1984 ( I  9). Data for cohort patients were collected every 3 mo 
in visits that consisted of a standardized medical history and collection of 
blood samples for HIV-1 serology and cellular immunology. The date of 
entry for participants already HIV-I seropositive at enrollment or the date 
of documented HIV-I seroconversion, taken as the midpoint between the 
last seronegative and the first HIV-I seropositive visit, was used as the 
reference point for clinical follow-up. For this study, seven cohort partic- 
ipants were studied: three patients who progressed to AIDS within 3 to 6 
yr after seroconversion (P039, P3S6, and PI21 I j and four participants who 
had I O  to > I  1 years of asymptomatic follow-up and  CD4+  T cell counts 
>SO0 cells/mm' (L016, L090, L6S8, and L709). 
Viral markers, comprising serum HIV-I RNA levels, and viral load, 
measured as the frequency of circulating CD4+ T cells productively in- 
fected with HIV- I ,  were determined as previously described (2). 
Recombinant vaccinia viruses (rVV) 
The rVV used in these studies were constructed from the Copenhagen 
strain of vaccinia virus and include rVV TC.4163 expressing RT of  HIV- 
1,-, and control-rVV 186-poly containing no insert (provided by Dr. Y .  
Riviere (Pasteur Institute, Paris, France) and Dr. M.  P. Kieny (Transgene 
S.A., Strasbourg,  France)). 
Expansion of HIV- 1 RT-specific CTL responses in  vitro 
Primed HIV-I-specific CTL precursors were expanded in vitro using a 
previously described method (2,  16) and that does not result in the expan- 
sion of naive Ag-specific CTL (M. Klein, unpublished observations). 
Briefly, PBMC isolated and cryopreserved at different time points during 
the study were thawed and resuspended in RPMI 1640 supplemented with 
antibiotics and IO% pooled human serum. Eight serial dilutions of PBMC 
ranging from 745 to 20,000 cells/well were seeded in 24 replicate wells in 
96-well round-bottom microtiter plates. Stimulator cells were autologous 
EBV-transformed B lymphoblastoid cell lines (B-LCL) infected with 5 
multiplicity of infection rVV-TC.4163 and subsequently inactivated with 
1 %  paraformaldehyde. To each well, IO" fixed stimulator cells and IOJ 
autologous PBMC (30 Cy irradiated) were added, and microcultures were 
maintained for 15 days at 37°C in S% CO,.  On days  2 and 9, cultures were 
fed medium containing 10 U/ml rIL-2 (kindly provided by Dr. R. Rom- 
bouts, Chiron B.V., Amsterdam, The Netherlands), and on day 7, they were 
restimulated with 10' tixed stimulator cells and rIL-2 ( I O  U/ml). On day 
15, wells were split, and effector cells were tested for cytotoxicity. All 
RT-specific lymphocyte cultures from the various time points were ex- 
panded by nonspecific restimulation with 2 X I O 4  irradiated (30  Cy) 
PBMC/well and SO00 irradiated (SO Cy) B-LCLlwell and medium con- 
taining rIL-2 (10 U/ml) and I pg/ml leukoagglutinin (PHA-leukocytes, 
Sigma Chemical Co., St. Louis, MO) and tested for cytotoxicity. Cultures 
from wells displaying a continuous high specific cytotoxicity for the en- 
dogenously processed Ag were expanded and tested for epitope specificity 
using peptide-pulsed autologous B-LCL as target cells. 
Peptides 
A set of 536 peptides spanning the entire sequence of HIV-lLA,  RT  (20) 
was synthesized as IO-amino acid-long peptides with an overlap of nine 
amino acids (e.g.: PI ,  PISPIETVPV; P2, ISPIETVPVK; P536, VPAHKG 
ICON). Peptides were synthesized by solid phase strategies on an auto- 
mated multiple peptide synthesizer (Abimed AMS 422, Langenfeld, Ger- 
many) using F-moc chemistry. Peptides were analyzed by reverse phase 
HPLC, dissolved in DMSO, and aliquoted. For cytotoxicity assays, pep- 
tides were diluted in 0.9% NaCl to a peptide concentration of 100 pg/ml 
and stored in  96-well V-bottom plates at -70°C. 
Cytotoxicity assays 
Standard "Cr release assays were performed as previously described (16). 
Briefly, autologous B-LCL were infected with 5 multiplicity of infection 
rVV-TG.4163 or rVV 186-poly and labeled with 100 pCi of Na2"CrO, 
(Amersham International, Aylesbury. U.K.)  for 16 h .  After three washes, 
4 X I@' target cells were added to each well. After 4 h, supernatants were 
harvested, and radioactivity was counted with a gamma counter (Cobra 11, 
Packard Instruments Co., Meriden, CT). Specific lysis (percentage) was 
calculated with the formula: 100 X ([experimental release ~ spontaneous 
release] t [maximum release - spontaneous release]). Spontaneous "Cr 
release was always < 1 S% of maximum release. 
Fine mapping of epitopej was performed by thawing the 96-well V- 
bottom plates containing the IO-mer peptides and transfer of S p1 from 
each well to 96-well U-bottom plates before addition of target cells. Au- 
tologous "Cr-labeled target cells (4 X IO ' )  were added in 45 @I and pre- 
incubated for 30 min at room temperature before the effector cells were 
added. The final concentration of peptide was 10 pg/ml. 
CTLp frequencies were determined as described previously (2). Briefly. 
wells were considered positive when "Cr release exceeded 10% specific 
lysis. Statistical analysis waj performed using methods previously de- 
scribed by Strijbosch et al. (21). CTLp frequencies are expressed as the 
number of  CTLp per IO" PBMC. RT-CTLp frequencies were computed as 
differences between CTLp frequencies determined on RT-expressing vs 
control targets. 
Results 
Analysis of RT-specific CTL response during the  natural 
history of  HIV- 1 infection 
We studied four LTS and three cohort participants who progressed 
to AIDS within 3 to 6 yr after HIV-I seroconversion. The three 
progressors in  our study showed a precipitous decline in CD4+ T 
cell counts during progression (data not shown). Clinical data for 
the studied subjects are presented in Table I. 
All seven HIV-1-positive individuals showed significant RT- 
specific CTL-mediated immune responses during their asymptom- 
atic period (Fig. 1). Subject PO39 showed a strong CTL response 
against RT in the first 18 mo after HIV-I seroconversion, with 
CTLp frequencies ranging from 300/10' to a peak of 4500/10' 
PBMC at 18 mo. Thereafter,  CTLp frequencies declined rapidly to 
undetectable levels. Subject P356 showed a strong CTL response, 
with CTLp frequencies in the range of 1000/10' PBMC for  6 yr, 
which then declined to undetectable levels. Of note, P356 devel- 
oped pneumocystic carinii pneumonia (PCP) 3 yr after serocon- 
version. CD4' T cell counts then stabilized at ?200 cells/mm' 
(data not shown), and CTL activity persisted up to 3 yr after PCP. 
Subject PI21 1 showed an RT-specific CTL response with CTLp 
frequencies ranging from 20/106 PBMC at seroconversion to a 
peak at 500 CTLpllO' PBMC at 18 mo. This subject also showed 
a decline in RT-specific CTLp, which became undetectable after 
diagnosis of AIDS (Fig. IA). 
Analysis of the CTLp frequencies of all three LTS revealed that 
they maintained persistent RT-specific CTL responses during > 10 
yr of follow-up. Subjects LO16 and L709 showed a stable RT- 
specific CTL response, with CTLp frequencies in the range of 20 
to 200/106 PBMC. Subjects LO90 and L658 showed CTLp fre- 
quencies between 200 and 1000/10" PBMC (Fig. le). 
Identification  of epitopes in RT recognized  by CTL from LTS 
Bulk cultures of CTL were expanded from all RT-specific wells of 
limiting dilution experiments performed to determine CTLp fre- 
quencies and tested for recognition of recombinant vaccinia- 
RT,,,-infected autologous B cell targets. To avoid skewing of the 
T cell repertoire toward a particular epitope, positive CTL bulk 
cultures were not cloned but were nonspecifically expanded for 2 
to 3 wk and subsequently retested against rVV-infected B-LCL 
and peptide-loaded B-LCL. Propagation of bulk cultures to the 
number of T cells necessary to scan the entire RT protein resulted 
in many cases in the outgrowth of nonspecific T cells. However. 
for each HIV- I -infected individual we succeeded in independently 
procuring RT-specific CTL populations from at least two PBMC 
samples obtained at different time points. 
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Table I .  Clinical data of LTS and progressors 
HIV-1  (Non-)Syncitium Serum TCID/l Oh 
HLA Class I Genotypes Factors Date Seroconversion ((N) SI) Diagnosis Event Copiesiml" T Cells'  (Years) 
CC-R5 Viral Seroconversion Age at Inducing AIDS HIV-1  RNA CD4' Follow-up 
LTS 
LO1 6 A*0201,29;B44,51 
Cw2,5 







PO39 A l ,  *0201 ;B*0801,44 
cw5,cw7 
P356 Af0201,28;B27,38 
c w 2  
P1211 A*0201,29;B44;Cw4 
WTlA32 01 -23-85 29 NSI 1 03-1 04.56 2-1 7 >11.5 
W T W  02-01  -85 41 NSI <lo3 <10 >11.5 
W T N T  09-25-86 37 NSI (103' (10 >IO.O 
WTM Deletions in 10-04-85 29 NSI 103-103.82 <IO 10.0 
nefand v 
pu genes 
WTW 10-30-87 36 SI 11-20-90  CAQ  10449-105 83 (10-323 3.1 
WTW 04-03-85 37 NSI 07-25-88 PCP 103.85-105 36 5-65  3.3 
WTm 03-1  7-87 26 NSI 01-11-93 C M  103-10592" 15-177 5.5 
a Range of serum HIV-1  RNA levels during  follow-up. ' Range of  viral  load  when measured as the  frequency  of  productively  HIV-1-infected  circulating  CD4+ T cells during  follow-up. 
'Serum  RNA levels dropped  below 10' copiesiml after initial 2.32-log reduction. 
dAn initial 5-log reduction  to <lo3 copiesiml  coincided  with  high levels of RT-specific CTL. 
From the four LTS studied, 12 CTL lines were obtained that 
could be used to scan the entire RT protein to determine the 
epitope specificity. This was performed by testing CTL against a 
set of 536 peptides, 10 amino acids long and overlapping by nine 
amino acids, spanning the entire RT protein of HIV-lmI. A total 
of six different epitopes were identified. Two CTL of L016, ob- 
tained from samples taken 6 yr apart, recognized only one peptide, 
EELRQHLLRW (Fig. 2 A ) .  All three CTL of LO90 recognized a 
single peptide, PIVLPEKDSW (Fig. 2B), whereas the four  CTL of 
L658 recognized two different peptides, SPIETVPVKL and 
EILKEPVHGV (Fig. 2C). From L709, three CTL were obtained 
that recognized two different peptides, KITTESIVIW and PIVLP 
EKDSW, the latter of which was shared with L090, and a set of 
five overlapping peptides that spans the sequence IVGAETFY 
VDGAAS (Fig. 20) .  Two of the recognized peptides derived from 
RT had already been defined by others (Table 11; peptide 308, 
EILKEPVHGV; peptide 434, IVGAETFYVDGAAS). 
Identification of epitopes in RT recognized by CTL from 
progressors 
From all three progressors studied we were able to establish seven 
CTL lines: three from P039, two from P356, and two  from P1211. 
These RT-specific CTL lines recognized a total of five different 
peptides. The three CTL lines of PO39 all recognized a different 
peptide. Peptide TWETWWTEYW was newly identified; the other 
two peptides, EELRQHLLRW and EILKEPVHGV, were also rec- 
ognized by CTL  from  LTS LO16 and L658 (Fig. 3A). CTL of P356 
recognized peptide IYQYMDDLYV (Fig. 3B), and CTL of P1211 
recognized peptides RETKLGKAGY and TWETWWTEYW, of 
which the latter peptide was also recognized by PO39 (Fig. 3C). 
Thus,  a total of five peptides were recognized, three of which were 
newly identified. The other two peptides (peptide 180, IYQYMD 
DLYV; peptide p308, EILKEPVHGV) had been identified as be- 
ing recognized by LTS in two other studies describing RT-derived 
epitopes (Table I1 and 111). 
Putative HLA class I restriction elements for RT-specific CTL 
CTL reacted with the overlapping peptides when the allele-specific 
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FIGURE 1. A, Progressors with high levels of RT-specific CTL activ- 
ity during the  asymptomatic phase. Diagnosis of AIDS is indicated by 
the arrow. B, LTS with persistent  levels of HIV-1 RT-specific CTL 
activity. 


































FIGURE 2. RT-derived epitopes recognized  by  four LTS at different time  points (A,  LO1 6; B, L090; C, L658; D, L709). The time  point  (tp)  indicates 
from  which  time  point sample CTL were  obtained; tp l  corresponds with  the first symbol of Figure 1, and tp2,3 indicates that CTL obtained  from 
time  points  2  and  3  recognized  the same peptide. vv-RT, target cells  infected  with r V V  TC.4163 (RT); vv-control, target cells  infected  with  rVV 
186-poly  (control). Shown is  the median  specific lysis of triplicate  wells. Effector and target cells  were  incubated at an E:T ratio of 3:l. 
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" M H C  class I restriction elements were identified by comparison of peptide sequences with known peptide-binding motifs (25) or by overlap in HLA types of 
'Amino  acid sequence according to HIV- lLAi  (20). Sometimes two  overlapping peptides were recognized; in that case, the peptide most likely  containing  the 
' Residues that are conserved in all clades are printed  in capitals, and  other residues are printed  in  lower case. Residues known to be  important for RT function are 
dThis CTL epitope was recognized by a LTS in the study of  Harrer et al.  (22)  and  by  a progressor in  our study. 
'These two epitopes  were  recognized by an HLA-B*5701  positive progressor who was studied for the  recognition of these two epitopes  especially. 
indivlduals  recognizing  this  peptide. 
complete CTL epitope 15 given. 
underlined (20, 26). 
but not always, two or three deca-peptides were recognized se- been shown to be restricted by HLA-A*0201 (23). LTS LO16 as 
quentially, depending mostly on the presence of the N-terminal well as progressor PO39 shared the HLA-B44 molecule, and pep- 
anchor. The CTL epitope located within peptide 180 (IYQYMD tide 203, which was recognized by both, fit the HLA-B44 peptide 
DLYV) has been reported to be recognized by HLA-A*O201-re- binding motif (24). Progressors PO39 and PI21 1 recognized pep- 
stricted CTL from LTS (22); this HLA type was shared with pro- tide 397, which also fit the HLA-B44 motif. Most likely, these 
gressor P356 in our study.  CTL from HLA-A2-positive individuals peptides were presented by HLA-B44. Peptide 243 (PIVLPE 
L658 and progressor PO39 both recognized peptide 308, which had KDSW), which was recognized by CTL from LO90 and L7O9, was 
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FIGURE 3. RT-derived epitope  recognized  by the three progressors at different time  points (A,  P039; B, P356; C, P1211). For explanatory notes, 
see Figure 2. 
Table 1 1 1 .  Degree of conservation of published HIV-1 reverse transcriptase-derived CTL epitopes 
Amino  Acid 
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Residues that are conserved in  all clades are printed  In capitals, and  other residues are printed  in  lower case 
Residues known to be important  for RT function are underlined 
HLA-B*5701 restricted. The optimal peptide lacked the N-termi- 
nal proline (data not shown). One of the other CTL of L709 rec- 
ognized peptide 374 (KITTESIVIW). This peptide also bound to 
HLA-B*5701 (our unpublished observations). As previously men- 
tioned, most CTL reacted with one or two IO-amino acid-long 
peptides containing the CTL epitope. One of the CTL from LTS 
L709 recognized at least five partially overlapping peptides (Fig. 
20) .  A sequence containing these peptides was reported to be 
restricted by HLA-A28 (25) (Table 111). Since subject L709 also 
displayed the HLA-A*6802 molecule, which is  a subtype of HLA- 
A28, this molecule is probably the restricting element. Peptide 448 
fit the recently published HLA-A29 peptide binding motif; indeed, 
this HLA molecule was also displayed by subject PI21 1 (26). 
Level of conservation of RT-derived CTL epitopes 
Among the published viral isolates, RT is the most conserved pro- 
tein of HIV-1 (20). This protein is essential for viral replication, 
and as such, the amino acid sequence conservation is thought to 
reflect both structural and functional constraints. This means that 
alterations in particular amino acids will result in loss of function 
or structure that probably leads to replication incompetent or de- 
fective viruses. It can be hypothesized that differences in the prop- 
erties of the RT-derived CTL epitopes chosen by the immune sys- 
tem may account for  a differential disease course, since mutations 
in less constrained epitopes may readily result in escape and sub- 
sequently reduced viral control (17). 
Inspection of the amino acid sequence of the nine RT-derived 
CTL epitopes showed that there was no difference in their degree 
of conservation (Table 11). These epitopes contained one to five 
residues that were not conserved compared with the sequenced 
viral isolates known to date. For example, peptide 243, recognized 
by CTL  from LTS LO90 and L709, and peptide 397, recognized by 
CTL from progressors PO39 and P1211, both contain five noncon- 
served residues (Table 11). In addition, LTS and progressors sim- 
ilarly recognized a peptide containing only one nonconserved res- 
idue (peptide 308;  Table 11). Furthermore, progressor P356 
recognized peptide 180, of which eight of nine residues have been 
reported to be under functional constraint. P356 developed AIDS 
The Journal of Immunology 3653 
within 3 yr, demonstrating that recognition of this epitope is by 
itself not protective. 
Next to the level of amino acid conservation, LTS might rec- 
ognize a distinct set of peptides, resulting in prolonged asymptom- 
atic survival. Two out of the nine epitopes were recognized by 
CTL from LTS as well as from progressors in the seven HIV-1- 
positive individuals tested here. Additionally, one of the epitopes 
recognized by progressor P356 was also reported to be recognized 
by CTL from a LTS reported by Harrer et al. (22). Two of the 
HLA-B*S701-restricted peptides (peptides 243 and 374) recog- 
nized by CTL from LTS LO90 and L709 were also recognized by 
CTL from an HLA-B*5701-positive progressor (Table 11) (our un- 
published observations). Recently, Goulder et al. reported two 
HIV- 1 gag-derived HLA-B57-restricted CTL epitopes that were 
recognized by LTS (27). Both epitopes were recognized by HLA- 
B57-restricted CTL from a rapid progressor, as reported previously 
by Johnson et al.  (28).  Thus, of these 1 1  epitopes, a total of seven 
were targets for CTL of both LTS and progressors. This suggests 
that epitopes recognized by CTL from both groups were not 
unique to either group. 
Discussion 
This study was designed to explore unique features of HIV-1- 
specific CTL of LTS. It was confirmed that neither the magnitude 
of the CTL response nor the number of target proteins or epitopes 
recognized distinguished LTS from rapid progressors (see Foot- 
note 5) (2, 7). Therefore, we evaluated the hypothesis that the 
quality of the CTL epitopes could be relevant for the patients rate 
of disease progression. Our data showed that all LTS and progres- 
sors studied here displayed strong RT-specific CTL responses dur- 
ing their asymptomatic phase. We observed that the CTLp fre- 
quencies of two LTS (LO16 and L709) were consistently lower. 
Interestingly, LO16 contained a  32-bp deletion in the P-chemokine 
receptor CC-R5, and in L709, all virus isolates contained a 12-bp 
deletion in neA which in both cases might have resulted in a lower 
number of CTL needed to control infection (29, 30). 
Using a method that allows for nonspecific expansion of primed 
T cells, we were able to expand at least two RT-specific CTL lines 
from different time points during the asymptomatic phase from 
each individual. A total of 19 different CTL lines identified nine 
different CTL  epitopes. When the number of amino acid residues 
varied between the different described viral isolates was taken as  a 
measure of conservation of the CTL epitope, no differences could 
be found in the degree of conservation between CTL epitopes rec- 
ognized by CTL from LTS and those from progressors. Both 
groups recognized peptides with one to five nonconserved residues 
(Table 11). Furthermore, addition of previously reported epitopes 
(Table 111) clearly shows that the level of conservation of CTL 
epitopes does not discriminate between LTS and progressors. 
Moreover,  one  epitope that is known to be under functional con- 
straint, IYQYMDDLYV, was recognized by an HIV-1-infected 
individual who progressed within 3 yr to AIDS. In contrast, others 
have reported that CTL from an LTS who remained asymptomatic 
for > I 8  yr recognized this epitope (22). Clearly, recognition of 
this epitope did not protect against progression to AIDS. However, 
true progression might have been delayed, since subject P356 
maintained RT-specific CTL  for about 3 yr and survived for  6 yr 
after the diagnosis of PCP. Alternatively, the difference in disease 
progression between LTS and progressors might be related to a 
unique set of CTL epitopes recognized by LTS. Five of seven 
identified epitopes were recognized by both LTS and progressors 
in this study. Moreover, despite recognition of these peptides, a 
rapid progression to AIDS was noted in those individuals who 
progressed. Our results extend those of Harrer et al., who noted 
that three gag and one RT-derived CTL epitopes were recognized 
not only by LTS, but by progressors as well (7). Taking into ac- 
count that two previously identified HLA-B57-restricted gag-de- 
rived epitopes were also recognized by CTL from LTS (27) and 
rapid progressor 010-063j in the study of Johnson et al. (28),  a total 
of 1 1  CTL epitopes, six of which were identified in RT, were 
recognized by both LTS and progressors. This demonstrates that 
there is no distinct set of CTL epitopes in RT or gag recognized 
by LTS. 
The question that remains is what makes an LTS? Since the 
time-to-AIDS appears to follow a Gaussian distribution, LTS rep- 
resent the tail end of the normal distribution. This is most likely 
due to favorable combinations of viral parameters, host genetics, 
antiviral immune responses, and environmental cofactors. One 
should anticipate that individual elements of these favorable com- 
binations might be found in each HIV-1-infected person. The mag- 
nitude, breadth, quality, and timing of the CTL response are among 
the features of HIV- 1 -specific CTL responses held responsible for 
efficient control of HIV-1 infection. It  is clearly demonstrated that 
neither the magnitude of the CTL response nor the breadth or the 
presence of a strong HIV- 1 -specific CTL response directed against 
epitopes under structural or functional constraints guarantees long 
term survival. One of the unexplored factors that might influence 
the course of disease is the timing of the onset of HIV- I -specific 
CTL responses upon primary infection. Early control of HIV-1 
infection, even before HIV-I is disseminated throughout the whole 
body, might extend the asymptomatic period or, in some rare 
cases, lead to sterilizing immunity. Frequently exposed, seroneg- 
ative individuals have been reported who display HIV-I-specific  T 
cell responses in the absence of clear-cut infection (31, 32). The 
timing of the immune response might also explain the results 
found in studies describing the resistance to HIV-I in individuals 
already infected with HIV-2 (33, 34). HIV-2 appears to be less 
transmissible and less pathogenic (35) than HIV-I, and in the 
Gambian prostitute cohort, CTL were found that were highly 
cross-reactive with HIV-I and HIV-2. This suggests that priming 
with a less virulent (i.e., HIV-2) virus strain might activate CTL 
able to recognize and abolish HIV-1 at transmission. HIV type 1 
and 2 cross-reactive CTL that are at the host’s disposal might deal 
quickly with freshly entered HIV-I . A cross-priming experiment in 
monkeys showed that indeed protection can be achieved following 
priming with a less pathogenic virus (36). 
Certain HLA molecules are frequently found in LTS (e.g., HLA- 
B27,B5 1 &B57), whereas others are found more frequently in pro- 
gressors (e.g., HLA-A24,B8,B35&Cw4) (37). This suggests that 
CTL responses restricted by certain HLA alleles may have a dif- 
ferent impact on disease progression. Two of the RT-derived CTL 
epitopes recognized by LTS, LO90 and L709, were presented in  the 
context of HLA-BS7. While these epitopes were also recognized 
by a progressor, this does not exclude that other HIV-I CTL 
epitopes are presented by HLA-B57 that significantly slow down 
disease progression. Whether such HLA-BS7 epitopes exist in LTS 
is currently under investigation. 
In conclusion, although it is generally accepted that CTL con- 
tribute to the control of HIV-1 replication, our data add to the 
growing idea that LTS do not differ from progressors with respect 
to the magnitude of the HIV-1-specific CTL responses, in the 
choice of target proteins, or in the functional quality of CTL 
epitopes recognized. Up until now, LTS were studied as a rela- 
tively homogeneous group of individuals who have remained 
asymptomatic for a long time. It is likely that favorable combina- 
tions of different factors (e.g., timing, breadth, magnitude, and 
specificity of CTL response; intact T helper responses; and host 
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and viral genetic factors) contribute to long term survival. There- 
fore, recording of genetic factors and clinical data of the HIV-1- 
infected subjects should be combined with full characterization of 
HIV- 1 -specific CTL responses together with the corresponding in 
vivo CTL epitope sequence variation data at different clinical 
stages of infection to determine which properties of the HIV-1- 
specific CTL response contribute to survival. 
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